实体器官移植受者新型冠状病毒感染诊疗专家共识(2023年版)  

Expert Consensus on the Management of SARS-CoV-2 Infection in Solid Organ Transplant Recipients(2023 edition)

作　　者：国家传染病医学中心 中华医学会器官移植学分会 中国康复医学会器官移植康复专业委员会 中国器官移植发展基金会器官移植受者健康管理专项基金 王正昕[2] 郑建铭 陈静瑜[4] 郑哲 霍枫 National Center for Infectious Diseases;Chinese Medical Association Organ Transplantation Branch;Organ Transplantation Rehabilitation Committee of the China Society of Rehabilitation Medicine;Special Fund for Health Management of Organ Transplant Recipients of the China Organ Transplantation Development Foundation;Wang Zhengzin;Zheng Jianming;Chen Jingyu;Zheng Zhe;Huo Feng(不详;Huashan Hospital,Fudan University,Institute of Organ Transplantation,Fudan University,Shanghai 200040;Department of Infection,Huashan Hospital,Fudan University,Shanghai 200040;Wuri People's Hospital,Wuri 214000;Fu Wai Hospital,Chinese Academy of Medical Sciences,Beijing 100037;Organ Transplant Recipient Health Management Special Fund,China Organ Transplant Development Foundation,Beijing 100010;General Hospital of Southern War Zone,Chinese People's Liberation Army,Guangzhou 510000)

机构地区：[1]不详 [2]复旦大学附属华山医院复旦大学器官移植研究所,上海200040 [3]复旦大学附属华山医院感染科,上海200040 [4]无锡市人民医院,无锡214000 [5]中国医学科学院阜外医院,北京100037 [6]中国器官移植发展基金会器官移植受者健康管理专项基金,北京100010 [7]中国人民解放军南部战区总医院,广州510000

出　　处：《中华器官移植杂志》2023年第3期129-145,共17页Chinese Journal of Organ Transplantation

基　　金：上海申康医院发展中心临床三年行动计划(SHDC2020CR2021B);国家自然科学基金专项项目(82241225);上海市重大专项(HS2021SHZX001)。

摘　　要：自2019年底以来,新型冠状病毒(新冠病毒)感染大流行已席卷全球。虽然目前的新冠病毒变异株的致病性和毒力已较原始株有所下降,大多数患者预后良好,但实体器官移植(SOT)受者人群为新冠病毒感染脆弱人群,即使全程接种新冠病毒疫苗,SOT受者感染新冠病毒的住院或死亡风险依然较高。SOT受者新冠病毒感染后其临床表现、诊断和治疗均与普通人群存在很大的特殊性,需要高度关注。目前尚缺乏针对SOT受者人群可供参考的新冠诊疗领域的指南或共识。因此,参考《新型冠状病毒诊疗方案(试行第十版)》及国内外文献,编写团队撰写了《实体器官移植受者新冠病毒感染诊疗专家共识(2023年版)》。本共识基于国内外新冠病毒感染的循证医学证据,并经过专家多次研讨达成一致意见后撰写成文,形成21条推荐意见,为SOT受者感染新冠病毒的诊疗提供参考。Since the end of 2019,the SARS-CoV-2 infection pandemic has swept the world.Although the current SARS-CoV-2 mutants have decreased in pathogenicity and virulence compared with the original strains,and most patients have a good prognosis,the solid organ transplant(SOT)recipients are vulnerable to SARS-CoV-2.And even with vaccination,the risk of hospitalization or death is still high in SOT recipients infected with SARS-CoV-2.What's more,the clinical manifestations,diagnosis and treatment strategy of SOT recipients infected with SARS-CoV-2 has its unique features,which need high attention.At present,there is a lack of guidelines or consensus in the diagnosis and treatment field of SARS-CoV-2 for such a large number of SOT recipients.Therefore,referring to the"Diagnosis and treatment plan of coronavirus(Trial Version 10)"and global published literature,the writing team wrote the"Expert consensus on diagnosis and treatment of COVID-19 in solid organ transplant recipients(2023 edition)".This consensus is evidence-based written and reached by experts after multiple rounds of discussions,forming 21 recommendations,providing reference for the diagnosis and treatment of SOT recipients infected with SARS-CoV-2.

关 键 词：实体器官移植 新型冠状病毒 诊断 治疗 

分 类 号：R511[医药卫生—内科学] R617[医药卫生—临床医学]